Fulltext present in this item

Thumbnail
Fulltext: 193607.pdf
Format: PDF
Description: publisher's version
Title: Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Author(s): Boer, S.M. de; Powell, M.E.; Mileshkin, L.; Katsaros, D.; Bessette, P.; Haie-Meder, C.; Ottevanger, P.B. ; Ledermann, J.A.; Khaw, P.; Colombo, A.; Fyles, A.; Baron, M.H.; Jurgenliemk-Schulz, I.M.; Kitchener, H.C.; Nijman, H.W.; Wilson, G.; Brooks, S.; Carinelli, S.; Provencher, D.M.; Hanzen, C.; Lutgens, L.C.; Smit, V.T.; Singh, N.; Do, V.; D'Amico, R.; Nout, R.A.; Feeney, A.; Verhoeven-Adema, K.W.; Snyers, A.; Putter, H.; Creutzberg, C.L.
Publication year: 2018
Source: Lancet Oncology, vol. 19, iss. 3, (2018), pp. 295-309
ISSN: 1470-2045
DOI: https://doi.org/10.1016/S1470-2045(18)30079-2
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/193607   https://hdl.handle.net/2066/193607

Display more details
Subject: All institutes and research themes of the Radboud University Medical Center
Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health Sciences
Tijdelijke code tbv inlezen publicaties Radboudumc - Alleen voor gebruik door Radboudumc
Organization: Medical Oncology
Radiation Oncology
Journal title:
Lancet Oncology
Volume: vol. 19
Issue: iss. 3
Page start: p. 295
Page end: p. 309

This item appears in the following Collection(s)

Browse

Statistics